S&P Futures
4,072.00 -12.25 (-0.30%) Dow Futures
33,967.00 -79.00 (-0.23%) Nasdaq Futures
12,174.00 -48.25 (-0.39%) Russell 2000 Futures
1,913.00 -6.50 (-0.34%) Crude Oil
79.62 -0.06 (-0.08%) Gold
1,941.60 -4.00 (-0.21%)
Virax Biolabs Group Limited (VRAX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.8440 |
| Open | 0.8500 |
| Bid | 0.7700 x 1200 |
| Ask | 0.8000 x 800 |
| Day's Range | 0.7670 - 0.8500 |
| 52 Week Range | 0.5400 - 29.0000 |
| Volume | |
| Avg. Volume | 1,392,670 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit
Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent. The specialized diagnostic kits can be found by contact
- PR Newswire
COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States
Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today that their supplier has received an Emergency Use Authorization ("EUA") from the U.S. FDA for their Over-the-Counter COVID-19 Rapid Antigen Test (the "Test"). The Tests are ready for sale in the US by Virax. Additionally, another Point of Care Rapid Antigen test to be distributed by Virax is seeking an ap
- PR Newswire
Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales
Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales.
